Regenxbio Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Regenxbio
RGNX Stock  USD 7.80  0.80  11.43%   
Regenxbio financial statements provide useful quarterly and yearly information to potential Regenxbio investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Regenxbio financial statements helps investors assess Regenxbio's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Regenxbio's valuation are summarized below:
Gross Profit
49.8 M
Profit Margin
(2.73)
Market Capitalization
350.6 M
Enterprise Value Revenue
2.3725
Revenue
83.3 M
We have found one hundred twenty available trending fundamental ratios for Regenxbio, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Regenxbio recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 1 B in 2025. Enterprise Value is likely to drop to about 944.4 M in 2025

Regenxbio Total Revenue

109.97 Million

Check Regenxbio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regenxbio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 17 M, Interest Expense of 16.3 M or Selling General Administrative of 50.8 M, as well as many indicators such as Price To Sales Ratio of 4.36, Dividend Yield of 0.0 or PTB Ratio of 1.55. Regenxbio financial statements analysis is a perfect complement when working with Regenxbio Valuation or Volatility modules.
  
Check out the analysis of Regenxbio Correlation against competitors.
For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.

Regenxbio Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets489.1 M466 M364.5 M
Slightly volatile
Short and Long Term Debt Total54.5 M82 M32.5 M
Slightly volatile
Other Current Liabilities45.4 M72.4 M34.5 M
Slightly volatile
Total Current Liabilities61.8 M103.2 M46.9 M
Slightly volatile
Accounts Payable23.9 M22.8 M8.7 M
Slightly volatile
Cash105 M57.5 M78.4 M
Slightly volatile
Non Current Assets Total200.7 M188 M149.4 M
Slightly volatile
Cash And Short Term Investments255.8 M234.7 M190.6 M
Slightly volatile
Net Receivables18.7 M20.5 M14.1 M
Slightly volatile
Common Stock Total Equity3.4 K3.6 K2.7 M
Slightly volatile
Common Stock Shares Outstanding35.1 M49.5 M28.6 M
Slightly volatile
Liabilities And Stockholders Equity489.1 M466 M364.5 M
Slightly volatile
Total Liabilities146.1 M206.3 M109.6 M
Slightly volatile
Total Current Assets288.4 M278 M215.1 M
Slightly volatile
Short Term Debt5.6 M7.9 M3.6 M
Slightly volatile
Common Stock4.8 K5 K2.7 M
Slightly volatile
Non Currrent Assets Other9.3 M16.7 M6.4 M
Slightly volatile
Other Assets10.8 M11.4 M75.2 M
Pretty Stable
Short Term Investments170.5 M177.2 M132.2 M
Slightly volatile
Long Term Investments9.7 M10.2 M71.7 M
Slightly volatile
Short and Long Term Debt3.1 M3.4 M3.8 M
Slightly volatile
Property Plant Equipment249.7 M237.8 M77.8 M
Slightly volatile
Other Liabilities58.5 M112.5 M43.5 M
Slightly volatile
Property Plant And Equipment Net107.3 M171.3 M67.8 M
Slightly volatile
Non Current Liabilities Total101.1 M103.1 M63.9 M
Slightly volatile
Capital Surpluse586.6 M1.1 B536.8 M
Slightly volatile
Property Plant And Equipment Gross255.8 M243.6 M85.2 M
Slightly volatile
Net Invested Capital463.6 M259.7 M319.8 M
Slightly volatile
Net Working Capital228.4 M174.8 M224.2 M
Slightly volatile
Long Term Debt Total4.7 M5.3 M5.7 M
Slightly volatile
Capital Lease Obligations69.6 M82 M34.9 M
Slightly volatile
Capital Stock4.6 K5 K4.1 K
Slightly volatile
Non Current Liabilities Other27.6 M29 M43.5 M
Slightly volatile

Regenxbio Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative50.8 M76.6 M38.8 M
Slightly volatile
Total Revenue110 M83.3 M83 M
Slightly volatile
Gross Profit88.3 M49.8 M66.8 M
Slightly volatile
Other Operating Expenses197.7 M316.7 M149.2 M
Slightly volatile
Research Development125.5 M208.5 M94.4 M
Slightly volatile
Cost Of Revenue21.7 M33.6 M16.2 M
Slightly volatile
Total Operating Expenses176.1 M283.1 M133 M
Slightly volatile
Interest Income165.3 K174 K1.5 M
Very volatile
Extraordinary Items607.2 K683.1 K744.8 K
Slightly volatile
Non Operating Income Net Other17.2 M8.7 M9.1 M
Slightly volatile
Reconciled Depreciation10.7 M16.2 M6.7 M
Slightly volatile

Regenxbio Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow34.7 M36.6 M71.3 M
Slightly volatile
End Period Cash Flow106.1 M59.6 M79.2 M
Slightly volatile
Net Borrowings1.9 M2.2 M2.4 M
Slightly volatile
Stock Based Compensation25.5 M38.5 M17.6 M
Slightly volatile
Depreciation17 M16.2 M6 M
Slightly volatile
Change To Netincome55.5 M52.8 M21.6 M
Slightly volatile
Issuance Of Capital Stock138.9 M132.3 M137.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.364.592740.051
Slightly volatile
Days Sales Outstanding80.1589.677592.3875
Pretty Stable
Stock Based Compensation To Revenue0.540.46160.3835
Pretty Stable
Capex To Depreciation0.140.15024.8132
Slightly volatile
EV To Sales4.644.886938.788
Slightly volatile
Inventory Turnover3.713.532.1192
Slightly volatile
Payables Turnover1.541.47241.7383
Slightly volatile
Sales General And Administrative To Revenue1.440.91951.2421
Very volatile
Research And Ddevelopement To Revenue2.932.50242.3345
Pretty Stable
Capex To Revenue0.02780.02920.254
Very volatile
Cash Per Share5.424.74035.431
Slightly volatile
Days Payables Outstanding332248310
Pretty Stable
Income Quality0.70.76230.8
Slightly volatile
Current Ratio2.562.6946.1091
Very volatile
Receivables Turnover3.874.07017.2154
Very volatile
Capex Per Share0.04670.04920.332
Slightly volatile
Revenue Per Share2.061.68312.1402
Slightly volatile
Interest Debt Per Share0.981.91260.865
Slightly volatile
Debt To Assets0.20.1760.164
Slightly volatile
Graham Number25.6631.4430.9234
Slightly volatile
Operating Cycle85.1989.6775274
Very volatile
Days Of Payables Outstanding332248310
Pretty Stable
Ebt Per Ebit1.080.97321.0144
Slightly volatile
Long Term Debt To Capitalization0.180.20.2181
Slightly volatile
Quick Ratio2.562.6946.008
Very volatile
Net Income Per E B T0.780.90.9673
Slightly volatile
Cash Ratio0.530.55752.1078
Very volatile
Days Of Sales Outstanding80.1589.677592.3875
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.171.01411.0564
Very volatile
Fixed Asset Turnover0.460.48646.254
Slightly volatile
Debt Ratio0.20.1760.164
Slightly volatile
Price Sales Ratio4.364.592740.051
Slightly volatile
Asset Turnover0.170.17880.8326
Slightly volatile
Gross Profit Margin0.850.59720.8114
Slightly volatile

Regenxbio Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1 B1.2 B1.2 B
Slightly volatile
Enterprise Value944.4 M1 B1 B
Slightly volatile

Regenxbio Fundamental Market Drivers

Cash And Short Term Investments234.7 M

Regenxbio Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Regenxbio Financial Statements

Regenxbio investors use historical fundamental indicators, such as Regenxbio's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Regenxbio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue115 K109.2 K
Total Revenue83.3 M110 M
Cost Of Revenue33.6 M21.7 M
Stock Based Compensation To Revenue 0.46  0.54 
Sales General And Administrative To Revenue 0.92  1.44 
Research And Ddevelopement To Revenue 2.50  2.93 
Capex To Revenue 0.03  0.03 
Revenue Per Share 1.68  2.06 
Ebit Per Revenue(2.80)(2.94)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Regenxbio Stock Analysis

When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY